Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Massimo Resti a Department of Paediatrics, University
of Florence, 50132 Florence, Italy, b Section of Paediatrics,
Department of Medicine, University of Chieti, Chieti, Italy
Correspondence to: Dr Azzari vierucci{at}cesit1.unifi.it
Members of the study group are listed at the end of the
paper.
Objective: To determine the risk factors for
and timing of vertical transmission of hepatitis C virus in women who are not infected with HIV-1.
Mother to child transmission of hepatitis C virus has been
extensively studied in mothers with HIV-1 infection.1-5
Previous reports have shown transmission rates ranging from 5.6% to
36%,
1 2 5
and the importance of HIV-1 coinfection in
mothers has been repeatedly emphasised.
2 5
Little is
known about the risk of mother to child transmission of hepatitis C
virus or the correlates and timing of infection in children born to
women who are HIV-1 seronegative. We conducted a multicentre
prospective study to assess this.
Nineteen centres participated in the study. All women who came to
the centres during pregnancy were tested for hepatitis C virus
antibodies. Women (and their babies) with confirmed hepatitis C
antibodies but negative for HIV-1 entered the study. History of blood
or blood product transfusions or intravenous drug use was carefully
investigated by face to face interviews with experienced paediatricians
using standardised questionnaires. Information was confirmed by
reviewing medical and drug addiction service records. Twelve mothers
admitted illicit drug use during pregnancy. Two babies had drug
withdrawal symptoms after birth. Each mother decided whether to breast
feed her baby. Caesarean section was decided for obstetric reasons
independent of maternal hepatitis C infection.
Blood samples were taken for measurement of alanine
aminotransferase, antihepatitis C virus, and anti-HIV-1 and for
hepatitis C virus polymerase chain reaction. Samples were obtained from mothers at the time of delivery and from infants at birth or as soon as
possible thereafter (but within three months after birth) and then at
least three times during the follow up (median 28 months, range 24-38).
Cord blood was never used for testing for hepatitis C virus. The
definition of breast fed or exclusively formula fed children was as
previously reported.6 Children were considered infected
when hepatitis C virus RNA was detected or when antibodies to the virus
persisted beyond age 2 years or reappeared after having disappeared.
Alanine aminotransferase concentrations were defined as raised if they
were higher than twice the upper limit of normal.
Laboratory methods
![]()
Abstract
Top
Abstract
Introduction
Patients and methods
Results
Discussion
References
Design: Follow up for a median of 28 (range
24-38) months of babies born to women with antibodies to hepatitis C
virus but not HIV-1.
Subjects: 442 mothers and babies, of whom 403 completed the study.
Main outcome measures: Presence of antibodies to
hepatitis C virus and viral RNA and alanine aminotransferase activity in babies. Presence of viral RNA, method of infection with hepatitis C,
method of delivery, and type of infant feeding in mothers.
Results: 13 of the 403 children had acquired
hepatitis C virus infection at the end of follow up. All these children were born to women positive for hepatitis C virus RNA; none of the 128 RNA negative mothers passed on the infection (difference 5%, 95%
confidence interval 2% to 7%). 6 children had viral RNA immediately
after birth. 111 women had used intravenous drugs and 20 had received
blood transfusions. 11 of the infected children were born to these
women compared with 2 to the 144 with no known risk factor (difference
7%, 2% to 12%).
Conclusions: This study suggests that in women not
infected with HIV only those with hepatitis C virus RNA are at risk of
infecting their babies. Transmission does seem to occur in utero, and
the rate of transmission is higher in women who have had blood
transfusions or used intravenous drugs than in women with no known risk
factor for infection.
Key messages
![]()
Introduction
Top
Abstract
Introduction
Patients and methods
Results
Discussion
References
![]()
Patients and methods
Top
Abstract
Introduction
Patients and methods
Results
Discussion
References
Antibodies to hepatitis C virus were evaluated by second
generation enzyme immunoassay (Ortho Diagnostic System, Raritan, NJ,
USA) and confirmed by western blotting (Innogenetics, Zwijndrecht, Belgium). Hepatitis C virus RNA was determined by a cDNA polymerase chain reaction with nested primers from the 5' untranslated region of
the virus.4 RNA was evaluated in plasma and in mothers' milk (supernatant and cells).
Statistical analysis
Data were processed with the SPSSX statistical
package. Ages and RNA copy numbers were reported as median and range.
Differences were evaluated by the non-parametric Mann-Whitney U test.
Differences in frequencies were evaluated by
2 test or
Fisher's exact probabilities. Relative risks of infection (and 95%
confidence intervals) and their significance were calculated with
EpiInfo Statcalc.7 Two tailed P values were used and
values below 0.05 defined as significant.
| |
Results |
|---|
|
|
|---|
Hepatitis C virus antibodies were found in 442 out of 25 654 (1.7%) women. Thirty nine (8.8%) mother-child pairs dropped out, and 403 completed the study. Medical history and clinical data did not differ in pairs who dropped out and in those who completed the study. Median follow up in the 403 children who completed the study was 28 (24-38) months. Hepatitis C virus RNA was found in 275 of 403 (68%) mothers (table 1).
|
All the infants had antibodies to hepatitis C virus at birth, but all those who did not have hepatitis C virus RNA lost the antibodies within 20 months (table 2). The clearance was slower in babies born to mothers with viral RNA.
|
Thirteen children born to the 275 women with hepatitis C virus RNA acquired the infection and became RNA positive (transmission rate 5%, 95% confidence interval 2% to 7%), whereas no child born to RNA negative mothers was infected. Six children had hepatitis C virus RNA immediately after birth. The transmission rate was higher in 20 recipients of blood transfusions (10%, 3% to 17%) and in 111 women with a history of intravenous drug use (8%, 5% to 11%) than in 144 women with no known risk factor (1%, 0.4% to 2%). The relative risk of transmission in women with no known risk of infection was significantly lower (0.17%, 0.04% to 0.73%; P=0.0063) compared with the risk in women who had been transfused or were intravenous drug users. Twelve mothers used drugs during pregnancy. One of their infants was infected with hepatitis C virus. Two infants had drug withdrawal symptoms; neither of them was infected.
Infection occurred in nine of 213 (4%) children born by vaginal delivery and in four of 62 (6%) born by caesarean section. The relative risk of infection in children born by vaginal delivery (0.65, 0.21 to 2.05) was not significantly different from that in children born by caesarean section (P=0.498). Six out of 87 (7%) breast fed and seven of 188 (4%) exclusively formula fed children were infected (relative risk 1.85, 0.64 to 5.35; P=0.358). Three out of six infected breast fed children had hepatitis C virus RNA detected on the day of birth.
Alanine aminotransferase abnormalities were found in all the infected children throughout the follow up. In five children concentrations fluctuated between normal and twice normal. In the other eight children concentrations were always higher than twice normal. In two of these eight children alanine aminotransferase concentrations had peaks more than 10 times normal.
Hepatitis C virus genotypes were analysed in all RNA positive babies and their mothers. Children and their mothers had identical genotypes: four had type 1a, six had type 1b, and one each had types 2a/2c, 3a, and 4c/4d.
Presence of virus was evaluated in all the mothers whose babies became RNA positive and in 258/262 mothers whose babies did not. There was no significant difference (z=0.380; P=0.704) in RNA load between mothers who transmitted the virus and those who did not (3.8 (0.02 to 56)×105 RNA copies/ml v 2.4 (0.01 to 92.7)×105 RNA copies/ml).
| |
Discussion |
|---|
|
|
|---|
Our study shows that vertical transmission of hepatitis C virus from HIV-1 negative mothers is infrequent (5%) but possible. In utero transmission of hepatitis C virus, which has been suggested,8 seems to occur since about half of infected babies were RNA positive immediately after birth. All the other babies were RNA positive at first examination within three months of birth, and in utero infection cannot be excluded.
The percentage of viraemic mothers among antibody positive mothers is similar to that reported in another population positive for hepatitis C virus antibodies.9 Intermittent viraemia is known to occur, and some women who were RNA negative immediately before delivery may have been viraemic during pregnancy. However, none of their children became RNA positive. In children born to RNA positive mothers the clearance of hepatitis C virus antibodies was slower than in children born to RNA negative mothers. This reflects the lower titres of antibodies found in RNA negative mothers (data not shown). The mean titre of antibodies has been shown to be higher in viraemic patients.10
Although asymptomatic, all infected infants developed alanine aminotransferase abnormalities during the first year of life, as reported in other studies. 1 2 11 Enzyme concentrations peaked between the sixth and 12th month.11
Delivery and feeding
Previous studies have suggested that vaginal delivery is a risk
factor for vertical transmission of hepatitis C virus and HIV-1 and
that caesarean section may reduce risk of HIV-1
infection.12 We found no increase in the rate of hepatitis
C transmission in children born by vaginal delivery, but the power of
the study and absence of elective caesarean deliveries do not allow
definite conclusions.
Source of maternal infection
The role of the source of hepatitis C infection in mothers is
still unclear. Mothers who were found to have antibodies for hepatitis
C virus during routine blood tests in pregnancy and who had no history
of drug misuse or transfusions seemed to have a lower probability of
infecting their babies. History of intravenous drug use itself,
independent of HIV-1 infection, may be an important predisposing factor
for perinatal transmission of hepatitis C virus. Immunological
modifications have been described in drug users14 that
could lead to an enhanced risk of vertical transmission of hepatitis C
virus. Moreover, placental damage occurs in drug using mothers, which
might have a role in fetal infection.14
Genotype
Most of the mothers of infected children in our study had
genotype 1b and 1a. The hepatitis C virus genotype pattern in the mothers of infected babies is similar to that found in a population of
Italian adults with chronic hepatitis.18 A study of
patients with normal liver function, however, reported a predominance
of genotype 2a.19 Given the low rate of virus transmission
the effect of genotype cannot be easily separated from other maternal factors in transmission of hepatitis C virus.
| |
Acknowledgments |
|---|
Members of the study group were C Adami Lami (Florence), C Benucci (Florence), P Bonazza (Grosseto), F Cantini (Pistoia), P Dal Poggetto (Prato), R Danieli (Livorno), A De Bernardi (Florence), P Del Carlo (Pietrasanta), P Gervaso (Florence), I Giani (Montepulciano), S G Gragnani (Cecina), E Marano (Borgo S Lorenzo), L Marrapodi (Pescia), G Messina (Poggibonsi), M Montesanti (Lucca), G Pellis (Fiesole), O Pieroni (Barga), M E Rossi (Florence), C Scarlato (Sansepolcro), M Strano (Montevarchi), M Turini (Empoli).
Contributors: MR initiated and coordinated the formulation of the primary study hypothesis, discussed core ideas, designed the protocol, and participated in clinical evaluation of patients, and analysis and writing of the paper. CA initiated and coordinated the formulation of the primary study hypothesis, discussed core ideas, designed the protocol, performed part of the laboratory tests, and participated in analysis and writing of the paper. FM and EN participated in the design and execution of the study, particularly data collection and documentation, interpreted the data, and contributed to the paper. MM discussed core ideas, participated in the protocol design, performed laboratory tests, participated in the analysis and interpretation of the data, and contributed to the paper. AV initiated the research and participated in study design, analysis, interpretation of the data, and writing the paper. MdeM participated in study design, data documentation, and statistical analysis, discussed core ideas, and contributed to writing the paper. All the authors gave their final approval to the revised version. Alison Evans gave statistical help, and Sergio Nanni, Wigi Sgarra, and Paolo Parigi gave technical help. MR is the study guarantor.
Funding: The research was partially supported by grant 394/A from Regione Toscana, III Programma Ricerca Sanitaria and by a grant from Ministero della Ricerca Scientifica.
Conflict of interest: None.
| |
References |
|---|
|
|
|---|
(Accepted 5 May 1998)